Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation
Yue Zhou(First Affiliated Hospital Zhejiang University), Tingbo Liang(Zhejiang Cancer Hospital)
Cited by 95
Related Papers
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
|Signal Transduction and Targeted Therapy|2021|594
Oncolytic virotherapy: basic principles, recent advances and future directions
|Signal Transduction and Targeted Therapy|2023|386
mRNA vaccines in disease prevention and treatment
|Signal Transduction and Targeted Therapy|2023|217